Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q99437

UPID:
VATO_HUMAN

ALTERNATIVE NAMES:
Vacuolar proton pump 21 kDa proteolipid subunit c''; hATPL

ALTERNATIVE UPACC:
Q99437; D3DPY5; Q6IB32

BACKGROUND:
V-type proton ATPase 21 kDa proteolipid subunit c'', or hATPL, is integral to the V-ATPase complex, responsible for proton translocation and intracellular pH regulation. By hydrolyzing ATP, it aids in maintaining the acidic environment of cellular compartments, a process vital for metabolism and cellular homeostasis. Its expression in the plasma membrane also contributes to the acidification of the extracellular space, highlighting its versatility and importance in cellular physiology.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of V-type proton ATPase 21 kDa proteolipid subunit c'' unveils potential avenues for therapeutic intervention, promising advancements in medical treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.